Replies to post #763153 on NorthWest Biotherapeutics Inc (NWBO)

[brooktrail1933]

Strongly agree. Also, look at his ratings wrt other "advisors". He's way down on the list, and his returns are in negative territory. With that kind of performance, why not pick up an extra 20K for writing a hit piece AF would be proud of. Lots of ice cream for the daughter with that kind of payday.
The timing and the very shaky analysis are too much to ignore.

[Investor082]

No excuses, please! The buck stops with LP. No non dilutive funding from big pharma and it’s only going to get increasingly worse.

[Guzzi62]

The Galzus Research hit piece in SA is maybe directed from A. Frankenstein himself?

I follow AF on X, and he haven't written anything about NWBO for a while because he is a coward and are afraid of the pending case where Citadel threw him out in front of a bus, I hope he ends up getting jail time but doubt it.

He is typically getting max 150 likes on X but more often below 30-40, so not very influential.

I can't read articles on SA any more being a free member, they tell me to pay, which I will never do, very few people have actually read it as you said.

No, it's not the article that took the SP down, that's for sure.

Being on the OTC sucks, we have to get out of there ASAP!

[Galzus Research]

Oh I for sure know very few of the critics here have read the article, given the kinds of things that I'm being accused of omitting.

Case in point of not bothering to do the most basic research: this pseudonym's first article was from November 2021: https://seekingalpha.com/article/4470668-inovio-pharmaceuticals-high-risk-but-possible-high-reward#source=author_id%3A106409%7Cauthor_slug%3Agalzus-research%7Ccontent_type%3Aall%7Cfirst_level_url%3Aauthor%7Csection_asset%3Aprofile_page_author_analysis%7Csection%3Aprofile_page_author

I was publishing under my real name from around 2014 to 2019, over 500 articles, and learned firsthand what happens when you put your name out there and voice concerns regarding cult stocks.

I will say that, despite the lack of comments on the article, it has reached an unusually high traffic amount relative to other biotech articles. If any of you guys were to actually come in and correct what you find is wrong, or report the article for inaccuracies, these would go a long way toward setting the record straight, or forcing me to, assuming the editorial team deems those criticisms valid.

But it's easier to push the narrative that this article is part of a manipulation scheme and to call for my doxing. Very few critiques of the article, and none so far that has been reasonable. Just "it's a hit piece." And if you think that, I don't think you've ever seen a hit piece.